On Secondary Patenting of Organic Compounds Suitable for use as Active Pharmaceutical Ingredients
- Авторы: Chernobrovkin M.1, Korlyukov A.2, Suponitskii K.2,3, Sinel’nikov A.4, Goizman M.1,5, Shimanovskii N.5,6, Zotova O.1, Ryzhkov I.1, Popova A.1,4
-
Учреждения:
- Drug Technology Co.
- A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
- G. V. Plekhanov Russian University of Economics
- People’s Friendship University of Russia
- Folium LLC
- N. I. Pirogov National Research Medical University
- Выпуск: Том 53, № 9 (2019)
- Страницы: 876-882
- Раздел: Discussion
- URL: https://journals.rcsi.science/0091-150X/article/view/246044
- DOI: https://doi.org/10.1007/s11094-019-02093-x
- ID: 246044
Цитировать
Аннотация
Secondary patenting of organic compounds that can undoubtedly be used as active pharmaceutical ingredients (APIs) is discussed. As a rule, such compounds, their synthetic pathways, and potential applications as APIs are patented several years before official authorization to use medicines containing them is obtained. This time lag stimulates attempted illegal secondary patenting of such APIs by new applicants. These attempts can be successful because of the extremely low level of patent review. As a rule, secondary patents contain unconfirmed experimental data and numerous errors, indicating that the applicant and experts lack sufficient professional training. In order to draw the attention of the scientific community to the problem, various aspects of it are discussed below using as examples secondary patents granted for six vitally important drugs used as APIs: abacavir sulfate, darunavir, dasatinib, lenalidomide, apalutamide, and enzalutamide. The appearance of such patents is shown to be inadmissible from scientific, ethical, and legal viewpoints.
Ключевые слова
Об авторах
M. Chernobrovkin
Drug Technology Co.
Email: goizmanmi@gmail.com
Россия, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
A. Korlyukov
A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Email: goizmanmi@gmail.com
Россия, 28 Vavilova St., Moscow, 119991
K. Suponitskii
A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences; G. V. Plekhanov Russian University of Economics
Email: goizmanmi@gmail.com
Россия, 28 Vavilova St., Moscow, 119991; 36 Stremyannyi Per., Moscow, 117997
A. Sinel’nikov
People’s Friendship University of Russia
Email: goizmanmi@gmail.com
Россия, 6 Miklukho-Maklaya St., Moscow, 117198
M. Goizman
Drug Technology Co.; Folium LLC
Автор, ответственный за переписку.
Email: goizmanmi@gmail.com
Россия, 2a Rabochaya St., Khimki, Moscow Oblast, 141400; Moscow, 127238
N. Shimanovskii
Folium LLC; N. I. Pirogov National Research Medical University
Email: goizmanmi@gmail.com
Россия, Moscow, 127238; 1 Ostrovityanova St., Moscow, 117997
O. Zotova
Drug Technology Co.
Email: goizmanmi@gmail.com
Россия, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
I. Ryzhkov
Drug Technology Co.
Email: goizmanmi@gmail.com
Россия, 2a Rabochaya St., Khimki, Moscow Oblast, 141400
A. Popova
Drug Technology Co.; People’s Friendship University of Russia
Email: goizmanmi@gmail.com
Россия, 2a Rabochaya St., Khimki, Moscow Oblast, 141400; 6 Miklukho-Maklaya St., Moscow, 117198